Corbus Pharmaceuticals HoldingsLTS:0SZI +0.84%47 PB Ratio is 1.35 as of Jul. 12, 2026, which is 59% below its 10-year median of 3.31. GuruFocus rates LTS:0SZI with a GF Score™ of 47/100 and a GF Value™ of $1.01 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,231 Biotechnology companies, Corbus Pharmaceuticals Holdings ranks better than 74.9% on this metric.
The historical rank and industry rank for Corbus Pharmaceuticals Holdings's PB Ratio or its related term are showing as below:
LTS:0SZI'
s PB Ratio Range Over the Past 10 Years
Min: 0.18 Med: 3.31 Max: 73.63
Current: 1.36
During the past 13 years, Corbus Pharmaceuticals Holdings's highest PB Ratio was 73.63. The lowest was 0.18. And the median was 3.31.
LTS:0SZI's PB Ratio is ranked better than 74.9% of 1231
companies
in the Biotechnology industry
Industry Median: 2.93
vs LTS:0SZI: 1.36
During the past 12 months, Corbus Pharmaceuticals Holdings's average Book Value Per Share Growth Rate was -31.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Corbus Pharmaceuticals Holdings was 66.30% per year. The lowest was -23.90% per year. And the median was 3.30% per year.
Back to Basics: PB Ratio
Corbus Pharmaceuticals Holdings (LTS:0SZI) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Corbus Pharmaceuticals Holdings PB Ratio Related Terms
Corbus Pharmaceuticals Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corbus Pharmaceuticals Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's PB Ratio falls into.
Corbus Pharmaceuticals Holdings PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Corbus Pharmaceuticals Holdings (LTS:0SZI) has a PB Ratio of 1.35 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Corbus Pharmaceuticals Holdings and its competitors. This is 59% below median its historical median of 3.31. Over the past decade, Corbus Pharmaceuticals Holdings' PB Ratio has ranged from 0.18 to 73.63. According to the industry distribution chart, Corbus Pharmaceuticals Holdings ranks #309 out of 1231 companies in the Biotechnology industry, placing it in the top 25.1%.
Is Corbus Pharmaceuticals Holdings' PB Ratio too high?
Corbus Pharmaceuticals Holdings' current PB Ratio of 1.35 is 59% below median its 10-year median of 3.31. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 73.63. The Biotechnology industry median PB Ratio is 2.93. Corbus Pharmaceuticals Holdings' value of 1.35 is 53.9% below this industry median. Based on the distribution chart, Corbus Pharmaceuticals Holdings ranks #309 out of 1231 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' PB Ratio compare to PRQR and NRXP?
According to the Biotechnology industry distribution chart, Corbus Pharmaceuticals Holdings ranks #309 out of 1231 companies for PB Ratio. This puts Corbus Pharmaceuticals Holdings in the upper half of its industry. The industry median PB Ratio is 2.93. Corbus Pharmaceuticals Holdings' value of 1.35 is 53.9% below this benchmark. Historically, Corbus Pharmaceuticals Holdings' own PB Ratio has ranged from 0.18 to 73.63 over the past decade. While the company's 10-year median is 3.31 vs. the industry median of 2.93, Corbus Pharmaceuticals Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corbus Pharmaceuticals Holdings's current PB Ratio of 1.35 is 53.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Corbus Pharmaceuticals Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corbus Pharmaceuticals Holdings's current PB Ratio is 1.35, which is 59% below median its own 10-year median of 3.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings (LTS:0SZI) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.01, compared to a current price of $9.61 — trading 851.5% above its estimated fair value. The current PB Ratio is 1.35, which is 59% below median its 10-year median of 3.31 and 53.9% below the Biotechnology industry median of 2.93. Corbus Pharmaceuticals Holdings' overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (LTS:0SZI), the current PB Ratio is 1.35 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corbus Pharmaceuticals Holdings (LTS:0SZI) Overvalued in 2026?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings stock appears to be overvalued.
The current stock price of $9.61 is trading 851.5% above its estimated GF Value™ of $1.01.
GuruFocus considers Corbus Pharmaceuticals Holdings to be Significantly Overvalued.
Key valuation signals for LTS:0SZI:
PB Ratio: 1.35 (59% below median its 10-year median of 3.31)
GF Value™: $1.01 vs. price of $9.61 (851.5% above fair value)
Industry Position: 53.9% below the Biotechnology median (#309 of 1231)
No single metric tells the full story. See the LTS:0SZI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corbus Pharmaceuticals Holdings Business Description
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
47GF Score
Get the complete analysis for LTS:0SZI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0SZI has been successfully added to your 
